CareRx (CRRX) Aandelenoverzicht
CareRx Corporation levert samen met haar dochterondernemingen apotheekdiensten aan bejaardentehuizen en andere zorginstellingen in Canada. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 3/6 |
CRRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CareRx Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | CA$3.51 |
| 52 Week Hoogtepunt | CA$4.00 |
| 52 Week Laag | CA$2.62 |
| Bèta | 0.62 |
| 1 maand verandering | -6.40% |
| 3 maanden verandering | -8.59% |
| 1 Jaar Verandering | 18.58% |
| 3 jaar verandering | 53.95% |
| 5 jaar verandering | -41.11% |
| Verandering sinds IPO | 13.23% |
Recent nieuws en updates
Narratiefupdate • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narratiefupdate • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Recent updates
Narratiefupdate • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narratiefupdate • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Narratiefupdate • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).
Narratiefupdate • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Narratiefupdate • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Narratiefupdate • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Narratiefupdate • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Narratiefupdate • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Narratiefupdate • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Narratiefupdate • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Narratiefupdate • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Narratiefupdate • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Analyseartikel • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nieuw narratief • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Analyseartikel • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Analyseartikel • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Analyseartikel • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Analyseartikel • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Analyseartikel • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • May 14
These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Rendement voor aandeelhouders
| CRRX | CA Consumer Retailing | CA Markt | |
|---|---|---|---|
| 7D | 1.2% | 0.8% | 1.5% |
| 1Y | 18.6% | 6.6% | 33.7% |
Rendement versus industrie: CRRX overtrof de Canadian Consumer Retailing industrie, die het afgelopen jaar een rendement 6.6 % opleverde.
Rendement versus markt: CRRX presteerde slechter dan Canadian Market, dat het afgelopen jaar een rendement van 33.7 % opleverde.
Prijsvolatiliteit
| CRRX volatility | |
|---|---|
| CRRX Average Weekly Movement | 3.5% |
| Consumer Retailing Industry Average Movement | 3.5% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 18.0% |
| 10% least volatile stocks in CA Market | 3.9% |
Stabiele aandelenkoers: CRRX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Canadian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van CRRX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2001 | 1,483 | Puneet Khanna | www.carerx.ca |
CareRx Corporation levert samen met haar dochterondernemingen apotheekdiensten aan bejaardentehuizen en andere zorginstellingen in Canada. Het bedrijf biedt medicatiebeheer, technologie en programmadiensten. Het bedrijf levert aan verzorgingshuizen, bejaardentehuizen, faciliteiten voor begeleid wonen en groepshuizen.
CareRx Corporation Samenvatting
| CRRX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | CA$225.24m |
| Inkomsten(TTM) | CA$27.07m |
| Inkomsten(TTM) | CA$374.61m |
8.2x
Koers/Winstverhouding0.6x
P/S-verhoudingIs CRRX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CRRX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | CA$374.61m |
| Kosten van inkomsten | CA$261.88m |
| Brutowinst | CA$112.74m |
| Overige uitgaven | CA$85.67m |
| Inkomsten | CA$27.07m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.43 |
| Brutomarge | 30.09% |
| Nettowinstmarge | 7.23% |
| Schuld/Eigen Vermogen Verhouding | 36.1% |
Hoe presteerde CRRX op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.3%
Huidig dividendrendement14%
UitbetalingsratioBetaalt CRRX een betrouwbaar dividend?
Zie CRRX dividendgeschiedenis en benchmarks| CareRx dividenddata | |
|---|---|
| Ex Dividend Datum | Jun 23 2026 |
| Betaaldatum dividend | Jul 09 2026 |
| Dagen tot Ex-dividend | 30 days |
| Dagen tot dividendbetaaldatum | 46 days |
Betaalt CRRX een betrouwbaar dividend?
Zie CRRX dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 16:43 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
CareRx Corporation wordt gevolgd door 11 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |